Hubei Zhenhua Chemical Co.,Ltd.

Hubei Zhenhua Chemical Co.,Ltd. primarily conducts its operations within China, specializing in the entire lifecycle of chromium salt products, from their development and manufacturing to their ultimate sale and distribution. Their comprehensive product portfolio includes a wide array of chromium-based compounds such as sodium bichromate, various forms of chromic acid anhydride (both crystalline and liquid), chrome oxide green, and potassium dichromate. Beyond these core offerings, the company also supplies vitamin K3, anhydrous sodium sulphate, and aluminium hydroxide. The firm boasts an international presence, exporting its goods to diverse global markets across Europe, the United States, Africa, and Southeast Asia. Established in 1967, Hubei Zhenhua Chemical Co.,Ltd. is headquartered in Huangshi, China, and was previously known as Huanghsi Zhenhua Chemical Industry Co., Ltd.

Hubei Zhenhua Chemical Co.,Ltd. trades as 603067.SS on SHH. The company is classified in Basic Materials / Chemicals and reports in CNY.

The current profile places the business in Chemicals. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Hubei Zhenhua Chemical Co.,Ltd. can be compared against peers such as Transfar Zhilian Co., Ltd., Hunan Nanling Industrial Explosive Materials Co., Ltd., Tinergy Chemical Co., Ltd., Zhejiang Yongtai Technology Co.,Ltd., Guangdong Dowstone Technology Co., Ltd., Shenzhen Senior Technology Material Co., Ltd..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $25.57B, beta of 0.67, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

603067.SS currently shows total debt of N/A and beta of 0.67. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.hszhenhua.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.